Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Authors:
- Michael J KorenMKMichael J Koren
- Rob ScottRSRob Scott
- Jae B KimJKJae B Kim
- Beat KnuselBKBeat Knusel
- Thomas LiuTLThomas Liu
- Lei LeiLLLei Lei
- Michael BologneseMBMichael Bolognese
- Scott M WassermanSWScott M Wasserman
- 1 December 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 380 (9858) , 1995-2006
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspectiveCurrent Opinion in Lipidology, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Genetic and Metabolic Determinants of Plasma PCSK9 LevelsThe Journal of Clinical Endocrinology & Metabolism, 2009
- Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosisJournal of Lipid Research, 2007
- Molecular biology of PCSK9: its role in LDL metabolismTrends in Biochemical Sciences, 2007
- Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed HyperlipidemiaJACC, 2006
- An Assessment of Statin Safety by HepatologistsThe American Journal of Cardiology, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- Compliance with Fluvastatin Treatment Characterization of the Noncompliant Population within a Population of 3845 Patients with HyperlipidemiaJournal of Clinical Epidemiology, 1999